Santhera Pharmaceuticals Holding AG (SANN.S)
16 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|57||Chairman of the Board|
|55||2017||Chief Executive Officer, Member of the Executive Management Board, Delegate of the Board|
|52||2017||Vice Chairman of the Board|
|58||2015||Chief Financial Officer, Member of the Executive Management Board|
|54||2015||Senior Vice President, General Counsel, Secretary to the Board, Member of the Executive Management Board|
- BRIEF-Santhera Says Obtains Worldwide Exclusive License From Polyphor
- BRIEF-Santhera Launches U.S. Expanded Access Program With Idebenone For Patients With DMD
- BRIEF-Santhera Pharmaceuticals Holding 2017 Revenues From Sales Of Raxone Up At CHF 22.9 Million
- BRIEF-Santhera: Negative CHMP Opinion On Appeal For Authorization Of Raxone
- BRIEF-Shares In Santhera Pharmaceuticals Holding AG Suspended From Trading Until Further Notice